Life Sciences
How Oligonucleotide Therapeutics May Change the Course of Rare Diseases
Broadcast Date: September 20, 2023Time: 9:00 am PT, 12:00 pm ET, 18:00 CET Using antisense oligonucleotides (ASOs) to treat patients with ultra-rare…
Broadcast Date: September 20, 2023
Time: 9:00 am PT, 12:00 pm ET, 18:00 CET
Using antisense oligonucleotides (ASOs) to treat patients with ultra-rare diseases is an incredibly exciting area. But the road from drug design to treatment is a long (and expensive) one.
On this GEN Live, we’ll discuss where ASO research is now, the challenges it faces as it moves forward, and the innovative new ways that those challenges are being overcome to treat patients. Dr. Stan Crooke, a pioneer in the field, founder of Ionis Pharmaceuticals and the n-Lorem Foundation, will join us for a broad discussion on the topic.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.
Founder and CEO, n-Lorem Foundation
Founder and Former CEO, Ionis Pharmaceuticals
Webinar produced with support from:
The post How Oligonucleotide Therapeutics May Change the Course of Rare Diseases appeared first on GEN – Genetic Engineering and Biotechnology News.
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….
